Your browser doesn't support javascript.
loading
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella, Alessandro; Nieves, Hector Cordero; Sborov, Douglas W; Cascione, Luciano; Radomska, Hanna S; Smith, Emily; Stiff, Andrew; Consiglio, Jessica; Caserta, Enrico; Rizzotto, Lara; Zanesi, Nicola; Stefano, Volinia; Kaur, Balveen; Mo, Xiaokui; Byrd, John C; Efebera, Yvonne A; Hofmeister, Craig C; Pichiorri, Flavia.
Afiliación
  • Canella A; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Nieves HC; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Sborov DW; Department of Internal Medicine, Oncology/Hematology Fellowship, The Ohio State University, Columbus, OH, USA.
  • Cascione L; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
  • Radomska HS; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Smith E; Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Stiff A; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Consiglio J; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Caserta E; Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA.
  • Rizzotto L; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Zanesi N; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Stefano V; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Kaur B; Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Università degli Studi, Ferrara, Italy.
  • Mo X; Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA.
  • Byrd JC; Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
  • Efebera YA; Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Hofmeister CC; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
  • Pichiorri F; Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
Oncotarget ; 14: 837-838, 2023 Sep 25.
Article en En | MEDLINE | ID: mdl-37747363
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos